vs
Amneal Pharmaceuticals, Inc.（AMRX）与TEREX CORP（TEX）财务数据对比。点击上方公司名可切换其他公司
TEREX CORP的季度营收约是Amneal Pharmaceuticals, Inc.的1.6倍（$1.3B vs $814.3M），TEREX CORP净利率更高（4.8% vs 4.3%，领先0.5%），Amneal Pharmaceuticals, Inc.同比增速更快（11.5% vs 6.2%），TEREX CORP自由现金流更多（$171.0M vs $108.5M），过去两年Amneal Pharmaceuticals, Inc.的营收复合增速更高（11.1% vs 1.0%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
特雷克斯公司是美国知名的设备制造企业，业务遍布美洲、欧洲、澳大利亚及亚太地区，主营物料加工机械、废弃物回收处理设备、移动式高空作业平台，以及电力行业专用设备，为全球多领域客户提供专业解决方案。
AMRX vs TEX — 直观对比
营收规模更大
TEX
是对方的1.6倍
$814.3M
营收增速更快
AMRX
高出5.2%
6.2%
净利率更高
TEX
高出0.5%
4.3%
自由现金流更多
TEX
多$62.5M
$108.5M
两年增速更快
AMRX
近两年复合增速
1.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $814.3M | $1.3B |
| 净利润 | $35.1M | $63.0M |
| 毛利率 | 36.5% | 18.8% |
| 营业利润率 | 13.8% | 10.4% |
| 净利率 | 4.3% | 4.8% |
| 营收同比 | 11.5% | 6.2% |
| 净利润同比 | 212.9% | 2963.6% |
| 每股收益（稀释后） | $0.10 | $0.95 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXTEX
| Q4 25 | $814.3M | $1.3B | ||
| Q3 25 | $784.5M | $1.4B | ||
| Q2 25 | $724.5M | $1.5B | ||
| Q1 25 | $695.4M | $1.2B | ||
| Q4 24 | $730.5M | $1.2B | ||
| Q3 24 | $702.5M | $1.2B | ||
| Q2 24 | $701.8M | $1.4B | ||
| Q1 24 | $659.2M | $1.3B |
净利润AMRXTEX
| Q4 25 | $35.1M | $63.0M | ||
| Q3 25 | $2.4M | $65.0M | ||
| Q2 25 | $22.4M | $72.0M | ||
| Q1 25 | $12.2M | $21.0M | ||
| Q4 24 | $-31.1M | $-2.2M | ||
| Q3 24 | $-156.0K | $88.0M | ||
| Q2 24 | $6.0M | $140.7M | ||
| Q1 24 | $-91.6M | $108.5M |
毛利率AMRXTEX
| Q4 25 | 36.5% | 18.8% | ||
| Q3 25 | 34.9% | 20.3% | ||
| Q2 25 | 39.5% | 19.6% | ||
| Q1 25 | 36.8% | 18.7% | ||
| Q4 24 | 36.0% | 15.9% | ||
| Q3 24 | 38.4% | 20.2% | ||
| Q2 24 | 35.6% | 23.8% | ||
| Q1 24 | 36.1% | 23.0% |
营业利润率AMRXTEX
| Q4 25 | 13.8% | 10.4% | ||
| Q3 25 | 9.0% | 10.1% | ||
| Q2 25 | 15.4% | 8.7% | ||
| Q1 25 | 14.4% | 5.6% | ||
| Q4 24 | 10.4% | 4.2% | ||
| Q3 24 | 12.6% | 10.1% | ||
| Q2 24 | 13.6% | 14.0% | ||
| Q1 24 | -1.6% | 12.2% |
净利率AMRXTEX
| Q4 25 | 4.3% | 4.8% | ||
| Q3 25 | 0.3% | 4.7% | ||
| Q2 25 | 3.1% | 4.8% | ||
| Q1 25 | 1.8% | 1.7% | ||
| Q4 24 | -4.3% | -0.2% | ||
| Q3 24 | -0.0% | 7.3% | ||
| Q2 24 | 0.9% | 10.2% | ||
| Q1 24 | -13.9% | 8.4% |
每股收益（稀释后）AMRXTEX
| Q4 25 | $0.10 | $0.95 | ||
| Q3 25 | $0.01 | $0.98 | ||
| Q2 25 | $0.07 | $1.09 | ||
| Q1 25 | $0.04 | $0.31 | ||
| Q4 24 | $-0.10 | $-0.03 | ||
| Q3 24 | $0.00 | $1.31 | ||
| Q2 24 | $0.02 | $2.08 | ||
| Q1 24 | $-0.30 | $1.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.0M | $772.0M |
| 总债务越低越好 | $2.6B | $2.6B |
| 股东权益账面价值 | $-70.8M | $2.1B |
| 总资产 | $3.7B | $6.1B |
| 负债/权益比越低杠杆越低 | — | 1.23× |
8季度趋势，按日历期对齐
现金及短期投资AMRXTEX
| Q4 25 | $282.0M | $772.0M | ||
| Q3 25 | $201.2M | $509.0M | ||
| Q2 25 | $71.5M | $374.0M | ||
| Q1 25 | $59.2M | $298.0M | ||
| Q4 24 | $110.6M | $388.0M | ||
| Q3 24 | $74.0M | $352.0M | ||
| Q2 24 | $43.8M | $319.3M | ||
| Q1 24 | $46.5M | $364.9M |
总债务AMRXTEX
| Q4 25 | $2.6B | $2.6B | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | $2.6B | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.4B | — |
股东权益AMRXTEX
| Q4 25 | $-70.8M | $2.1B | ||
| Q3 25 | $-109.5M | $2.0B | ||
| Q2 25 | $-112.1M | $2.0B | ||
| Q1 25 | $-131.7M | $1.8B | ||
| Q4 24 | $-109.3M | $1.8B | ||
| Q3 24 | $-93.4M | $2.0B | ||
| Q2 24 | $-57.5M | $1.8B | ||
| Q1 24 | $-63.7M | $1.7B |
总资产AMRXTEX
| Q4 25 | $3.7B | $6.1B | ||
| Q3 25 | $3.6B | $6.2B | ||
| Q2 25 | $3.4B | $6.2B | ||
| Q1 25 | $3.4B | $5.8B | ||
| Q4 24 | $3.5B | $5.7B | ||
| Q3 24 | $3.5B | $3.8B | ||
| Q2 24 | $3.5B | $3.8B | ||
| Q1 24 | $3.5B | $3.8B |
负债/权益比AMRXTEX
| Q4 25 | — | 1.23× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.41× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.3M | $205.0M |
| 自由现金流经营现金流 - 资本支出 | $108.5M | $171.0M |
| 自由现金流率自由现金流/营收 | 13.3% | 13.0% |
| 资本支出强度资本支出/营收 | 2.7% | 2.6% |
| 现金转化率经营现金流/净利润 | 3.72× | 3.25× |
| 过去12个月自由现金流最近4个季度 | $269.9M | $322.0M |
8季度趋势，按日历期对齐
经营现金流AMRXTEX
| Q4 25 | $130.3M | $205.0M | ||
| Q3 25 | $118.5M | $154.0M | ||
| Q2 25 | $83.8M | $102.0M | ||
| Q1 25 | $7.4M | $-21.0M | ||
| Q4 24 | $118.1M | $177.0M | ||
| Q3 24 | $141.8M | $116.4M | ||
| Q2 24 | $39.7M | $66.5M | ||
| Q1 24 | $-4.4M | $-33.9M |
自由现金流AMRXTEX
| Q4 25 | $108.5M | $171.0M | ||
| Q3 25 | $106.2M | $130.0M | ||
| Q2 25 | $61.0M | $78.0M | ||
| Q1 25 | $-5.8M | $-57.0M | ||
| Q4 24 | $102.9M | $128.0M | ||
| Q3 24 | $124.8M | $87.4M | ||
| Q2 24 | $29.0M | $42.5M | ||
| Q1 24 | $-13.6M | $-68.9M |
自由现金流率AMRXTEX
| Q4 25 | 13.3% | 13.0% | ||
| Q3 25 | 13.5% | 9.4% | ||
| Q2 25 | 8.4% | 5.2% | ||
| Q1 25 | -0.8% | -4.6% | ||
| Q4 24 | 14.1% | 10.3% | ||
| Q3 24 | 17.8% | 7.2% | ||
| Q2 24 | 4.1% | 3.1% | ||
| Q1 24 | -2.1% | -5.3% |
资本支出强度AMRXTEX
| Q4 25 | 2.7% | 2.6% | ||
| Q3 25 | 1.6% | 1.7% | ||
| Q2 25 | 3.2% | 1.6% | ||
| Q1 25 | 1.9% | 2.9% | ||
| Q4 24 | 2.1% | 3.9% | ||
| Q3 24 | 2.4% | 2.4% | ||
| Q2 24 | 1.5% | 1.7% | ||
| Q1 24 | 1.4% | 2.7% |
现金转化率AMRXTEX
| Q4 25 | 3.72× | 3.25× | ||
| Q3 25 | 50.00× | 2.37× | ||
| Q2 25 | 3.74× | 1.42× | ||
| Q1 25 | 0.61× | -1.00× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.32× | ||
| Q2 24 | 6.62× | 0.47× | ||
| Q1 24 | — | -0.31× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
TEX
| Aerials Segment | $466.0M | 35% |
| Materials Processing Segment | $428.0M | 32% |
| Materials Processing Equipment | $279.0M | 21% |
| Specialty Equipment | $148.0M | 11% |
